ORLANDO--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported Phase I results from an ongoing open-label, multi-center study evaluating safety and tolerability of MLN4924 in patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndromes (MDS). These data were announced during an oral presentation at the 52nd annual meeting of the American Society of Hematology (ASH), held December 4-7 in Orlando, Florida.
